What happened Genzyme stock?
What happened Genzyme stock?
WASHINGTON (Reuters) – Sanofi-Aventis SASY.PA said it has completed its takeover of U.S. biotechnology company Genzyme Corp GENZ. Sanofi said more than 237 million Genzyme shares were tendered in the transaction, representing 89.4 percent of outstanding shares. …
Is Genzyme publicly traded?
GENZ – Stock Price, News, Charts, Message Board, Trades….Genzyme Quote Info.
| Trades | 0 |
|---|---|
| Currency | USD |
| Market | NASDAQ |
| Type | Common Stock |
Is Sanofi and Genzyme the same?
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi.
Is SNY a buy?
Zacks’ proprietary data indicates that Sanofi is currently rated as a Zacks Rank 3 and we are expecting an inline return from the SNY shares relative to the market in the next few months. Valuation metrics show that Sanofi may be undervalued. Its Value Score of B indicates it would be a good pick for value investors.
Who bought Genzyme?
Sanofi-Aventis SA
With its agreement to purchase Genzyme Corp. for more than $20 billion, France’s Sanofi-Aventis SA becomes the latest global drug giant to acquire a research base in Cambridge, Mass., one of the industry’s hottest locales for cutting-edge science.
When did Sanofi go public?
Sanofi shares have been listed on Euronext Paris since May 25, 1999. They were also listed on the New York Stock Exchange in the form of ADSs (American Depositary Shares) between July 1, 2002 and December 31, 2018. Since January 2, 2019, Sanofi ADSs are listed on the Nasdaq Global Select Market (Nasdaq).
Is Sanofi part of Genzyme?
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology, and oncology.
How do I buy stock in SNY?
To purchase Sanofi ADRs, shareholders may contact a licensed stockbroker or may buy directly from our ADR depository bank, JPMorgan, through Direct Purchase Plan.
Is Sanofi a buy or sell?
SNY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 12.64, while its industry has an average P/E of 14.77.
Why did Sanofi buy Genzyme?
“Genzyme is really the gold standard in patient-centric care and we believe the Genzyme brand will be able to protect that franchise,” he said. Sanofi predicted the deal, which is expected to close early in the second quarter, would lift its underlying earnings by between 0.75 and 1.0 euro per share by 2013.
